Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2017, 51293-51298 [2017-24009]
Download as PDF
<![CDATA[
ethrower on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices
(‘‘the ’557 patent’’). The complaint
further alleges that an industry in the
United States exists as required by the
applicable Federal Statute.
The complainant requests that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and cease and
desist orders.
ADDRESSES: The complaint, except for
any confidential information contained
therein, is available for inspection
during official business hours (8:45 a.m.
to 5:15 p.m.) in the Office of the
Secretary, U.S. International Trade
Commission, 500 E Street SW., Room
112, Washington, DC 20436, telephone
(202) 205–2000. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov. The public
record for this investigation may be
viewed on the Commission’s electronic
docket (EDIS) at https://edis.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Katherine Hiner, The Office of
Secretary, Docket Services, U.S.
International Trade Commission,
telephone (202) 205–1802.
SUPPLEMENTARY INFORMATION:
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C. 1337
and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2017).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
October 30, 2017, Ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(B) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain wafer-level
packaging semiconductor devices and
products containing same (including
cellular phones, tablets, laptops, and
notebooks) and components thereof by
reason of infringement of one or more of
claims 1–8 of the ’557 patent and claims
1–18 of the ’001 patent; and whether an
industry in the United States exists as
VerDate Sep<11>2014
16:18 Nov 02, 2017
Jkt 244001
required by subsection (a)(2) of section
337;
(2) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainant is: Tessera
Advanced Technologies, Inc., 3025
Orchard Parkway, San Jose, CA 95134.
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
Samsung Electronics Co., Ltd., 129
Samsung-ro, Maetan-3dong, Yeongtonggu, Suwon-si, Gyeonggi-do, Republic of
Korea 443–742.
Samsung Electronics America, Inc., 85
Challenger Road, Ridgefield Park, NJ
07660.
Samsung Semiconductor, Inc., 3655
N. 1st Street, San Jose, CA 95134.
(3) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
The Office of Unfair Import
Investigations will not participate as a
party in this investigation.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), such
responses will be considered by the
Commission if received not later than 20
days after the date of service by the
Commission of the complaint and the
notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
51293
Issued: October 31, 2017.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2017–24004 Filed 11–2–17; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–470F]
Final Adjusted Aggregate Production
Quotas for Schedule I and II Controlled
Substances and Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2017
Drug Enforcement
Administration (DEA), Department of
Justice (DOJ).
ACTION: Final order.
AGENCY:
This final order establishes
the final adjusted 2017 aggregate
production quotas for controlled
substances in schedules I and II of the
Controlled Substances Act and the
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
SUMMARY:
This order is applicable
November 3, 2017.
DATES:
FOR FURTHER INFORMATION CONTACT:
Michael J. Lewis, Diversion Control
Division, Drug Enforcement
Administration, 8701 Morrissette Drive,
Springfield, VA 22152, Telephone: (202)
598–6812.
SUPPLEMENTARY INFORMATION:
Legal Authority
Section 306 of the Controlled
Substances Act (CSA) (21 U.S.C. 826)
requires the Attorney General to
establish aggregate production quotas
for each basic class of controlled
substances listed in schedules I and II
and for the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine. The Attorney
General has delegated this function to
the Administrator of the Drug
Enforcement Administration (DEA)
pursuant to 28 CFR 0.100.
Background
The DEA published the 2017
established aggregate production quotas
for controlled substances in schedules I
and II and for the assessment of annual
needs for the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine in the Federal
Register on October 5, 2016. 81 FR
69079. This notice stated that the
E:\FR\FM\03NON1.SGM
03NON1
51294
Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices
Administrator would adjust, as needed,
the established aggregate production
quotas in 2017 in accordance with 21
CFR 1303.13 and 21 CFR 1315.13. The
2017 proposed adjusted aggregate
production quotas for controlled
substances in schedules I and II and
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine were
subsequently published in the Federal
Register on August 4, 2017, (82 FR
36449) in consideration of the outlined
criteria. All interested persons were
invited to comment on or object to the
proposed adjusted aggregate production
quotas and assessment of annual needs
on or before September 5, 2017.
Comments Received
Three DEA-registered entities
submitted timely comments regarding a
total of eleven schedule I and II
controlled substances. Comments
received proposed that the aggregate
production quotas for amphetamine (for
conversion), dihydrocodeine,
diphenoxylate (for sale), heroin,
levorphanol, lisdexamfetmine,
methadone intermediate,
noroxymorphone (for conversion),
oripavine, oxycodone (for sale), and
oxymorphone (for conversion) were
insufficient to provide for the estimated
medical, scientific, research, and
industrial needs of the United States, for
export requirements, and for the
establishment and maintenance of
reserve stocks. The DEA received 43
comments from non-DEA registered
entities in response to the DEA’s August
4, 2017, press release for the proposed
2018 aggregate production quotas. The
majority of these commenters expressed
concerns about the 20 percent decrease
to the production quotas of controlled
substances. The DEA also received two
comments from non-DEA registered
entities suggesting that the rescheduling
of marihuana would drastically reduce
opioid use, misuse, and addiction.
These 45 comments addressed issues
that were outside the scope of this final
order, and therefore are not relevant to
the analysis involved in finalizing the
2017 aggregate production quotas.
The DEA received no comments from
DEA-registered or non-DEA registered
entities for previously established
values of the 2017 assessment of annual
needs for ephedrine, pseudoephedrine,
and phenylpropanolamine.
Analysis for Final Adjusted 2017
Aggregate Production Quotas and
Assessment of Annual Needs
In determining the final adjusted 2017
aggregate production quotas and
assessment of annual needs, the DEA
has taken into consideration the above
comments that are specifically relevant
to this Final Order for calendar year
2017 along with the factors set forth in
21 CFR 1303.13 and 21 CFR 1315.13 in
accordance with 21 U.S.C. 826(a), and
other relevant factors including the 2016
year-end inventories, initial 2017
manufacturing and import quotas, 2017
export requirements, actual and
projected 2017 sales, research and
product development requirements, and
additional applications received. Based
on all of the above, the Administrator is
adjusting the 2017 aggregate production
quotas and assessment of annual needs
for 4-Anilino-N-Phenethyl-4-Piperidine
(ANPP), dihydrocodeine, ephedrine (for
sale), fentanyl, hydrocodone (for sale),
meperidine, methadone intermediate,
morphine (for sale), opium (tincture),
Oripavine, oxycodone (for sale),
Oxymorphone (for conversion),
Oxymorphone (for sale),
phenylpropanolamine (for conversion),
phenylpropanolamine (for sale),
pseudoephedrine (for sale), tapentadol,
and thiafentanil. This final order reflects
those adjustments.
Regarding diphenoxylate (for sale),
heroin, levorphanol, and
noroxymorphone (for conversion) the
Administrator hereby determines that
the proposed adjusted 2017 aggregate
production quotas and assessment of
annual needs for these substances and
list I chemicals as published on August
4, 2017, (82 FR 36449) are sufficient to
meet the current 2017 estimated
medical, scientific, research, and
industrial needs of the United States
and to provide for adequate reserve
stock. This final order establishes these
aggregate production quotas at the same
amounts as proposed.
Pursuant to the above, the
Administrator hereby finalizes the 2017
aggregate production quotas for the
following schedule I and II controlled
substances and the 2017 assessment of
annual needs for the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine, expressed in
grams of anhydrous acid or base, as
follows:
Final revised
2017 quotas
(g)
Basic class
ethrower on DSK3G9T082PROD with NOTICES
Schedule I
1-(1-Phenylcyclohexyl)pyrrolidine ......................................................................................................................................................
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ..........................................................................................................................
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) .........................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine .................................................................................................................................................
1-Benzylpiperazine ............................................................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine .........................................................................................................................................
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) .........................................................................................................................
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ......................................................................................................................
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) ........................................................................................................................
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) ....................................................................................................................
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) .....................................................................................................................................
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) ......................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ......................................................................................................................
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) ......................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) ............................................................................................................................
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I–NBOMe; 2C-I–NBOMe; 25I; Cimbi-5) ..............................
2,5-Dimethoxy-4-ethylamphetamine (DOET) ....................................................................................................................................
2,5-Dimethoxy-4-n-propylthiophenethylamine ...................................................................................................................................
2,5-Dimethoxyamphetamine ..............................................................................................................................................................
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) ..............................................................................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) ........................................................................................................
3,4,5-Trimethoxyamphetamine ..........................................................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) ..........................................................................................................................................
VerDate Sep<11>2014
16:18 Nov 02, 2017
Jkt 244001
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
E:\FR\FM\03NON1.SGM
03NON1
10
30
30
15
25
2
30
30
30
30
30
25
30
25
30
30
25
25
25
30
30
25
55
Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices
Final revised
2017 quotas
(g)
ethrower on DSK3G9T082PROD with NOTICES
Basic class
3,4-Methylenedioxymethamphetamine (MDMA) ...............................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ...........................................................................................................................
3,4-Methylenedioxy-N-methylcathinone (methylone) ........................................................................................................................
3,4-Methylenedioxypyrovalerone (MDPV) .........................................................................................................................................
3-FMC; 3-Fluoro-N-methylcathinone .................................................................................................................................................
3-Methylfentanyl .................................................................................................................................................................................
3-Methylthiofentanyl ...........................................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (DOB) ....................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ...............................................................................................................................
4-Fluoroisobutyryl fentanyl .................................................................................................................................................................
4-FMC; Flephedrone ..........................................................................................................................................................................
4-MEC; 4-Methyl-N-ethylcathinone ....................................................................................................................................................
4-Methoxyamphetamine ....................................................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) ....................................................................................................................................
4-Methylaminorex ..............................................................................................................................................................................
4-Methyl-N-methylcathinone (mephedrone) ......................................................................................................................................
4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) .............................................................................................................................
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol .......................................................................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) .........................
5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ..........................
5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) .................................................................
5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) ......................................................
5-Fluoro-PB-22; 5F-PB-22 .................................................................................................................................................................
5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ..........................................
5-Methoxy-3,4-methylenedioxyamphetamine ....................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ................................................................................................................................................
5-Methoxy-N,N-dimethyltryptamine ...................................................................................................................................................
AB-CHMINACA ..................................................................................................................................................................................
AB-FUBINACA ...................................................................................................................................................................................
AB-PINACA ........................................................................................................................................................................................
Acetyl Fentanyl ..................................................................................................................................................................................
Acetyl-alpha-methylfentanyl ...............................................................................................................................................................
Acetyldihydrocodeine .........................................................................................................................................................................
Acetylmethadol ..................................................................................................................................................................................
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ................................
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ....................................................
AH-7921 .............................................................................................................................................................................................
Allylprodine ........................................................................................................................................................................................
Alphacetylmethadol ............................................................................................................................................................................
alpha-Ethyltryptamine ........................................................................................................................................................................
Alphameprodine .................................................................................................................................................................................
Alphamethadol ...................................................................................................................................................................................
alpha-Methylfentanyl ..........................................................................................................................................................................
alpha-Methylthiofentanyl ....................................................................................................................................................................
alpha-Methyltryptamine (AMT) ..........................................................................................................................................................
alpha-Pyrrolidinobutiophenone (a-PBP) ............................................................................................................................................
alpha-Pyrrolidinopentiophenone (a-PVP) ..........................................................................................................................................
Aminorex ............................................................................................................................................................................................
APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) .......................................................................................
Benzylmorphine .................................................................................................................................................................................
Betacetylmethadol .............................................................................................................................................................................
beta-Hydroxy-3-methylfentanyl ..........................................................................................................................................................
beta-Hydroxyfentanyl .........................................................................................................................................................................
beta-Hydroxythiofentanyl ...................................................................................................................................................................
Betameprodine ...................................................................................................................................................................................
Betamethadol .....................................................................................................................................................................................
Betaprodine ........................................................................................................................................................................................
Bufotenine ..........................................................................................................................................................................................
Butylone .............................................................................................................................................................................................
Butyryl Fentanyl .................................................................................................................................................................................
Cathinone ...........................................................................................................................................................................................
Codeine Methylbromide .....................................................................................................................................................................
Codeine-N-oxide ................................................................................................................................................................................
Desomorphine ....................................................................................................................................................................................
Diethyltryptamine ...............................................................................................................................................................................
Difenoxin ............................................................................................................................................................................................
Dihydromorphine ................................................................................................................................................................................
Dimethyltryptamine ............................................................................................................................................................................
Dipipanone .........................................................................................................................................................................................
Etorphine ............................................................................................................................................................................................
Fenethylline ........................................................................................................................................................................................
Furanyl Fentanyl ................................................................................................................................................................................
VerDate Sep<11>2014
16:18 Nov 02, 2017
Jkt 244001
PO 00000
Frm 00086
Fmt 4703
51295
Sfmt 4703
E:\FR\FM\03NON1.SGM
03NON1
50
40
40
35
25
30
30
25
25
30
25
25
150
25
25
45
25
50
40
30
30
30
20
25
25
25
25
30
50
30
100
30
30
2
30
50
30
2
2
25
2
2
30
30
25
25
25
25
25
30
2
30
30
30
2
4
2
3
25
30
24
30
330
25
25
8,750
1,566,000
35
5
30
30
30
51296
Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices
Final revised
2017 quotas
(g)
Basic class
gamma-Hydroxybutyric acid ..............................................................................................................................................................
Heroin ................................................................................................................................................................................................
Hydromorphinol ..................................................................................................................................................................................
Hydroxypethidine ...............................................................................................................................................................................
Ibogaine .............................................................................................................................................................................................
JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) ....................................................................................................................
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) .........................................................................................................................................
JWH-073 (1-Butyl-3-(1-naphthoyl)indole) ..........................................................................................................................................
JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) .....................................................................................................................
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) .........................................................................................................................
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) .............................................................................................................
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) ..........................................................................................................................
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) ......................................................................................................................
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) ..........................................................................................................................
Lysergic acid diethylamide (LSD) ......................................................................................................................................................
MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3carboxamide) ..................................................................................................................................................................................
MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) ...............
MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .........................................
Marihuana ..........................................................................................................................................................................................
Mecloqualone .....................................................................................................................................................................................
Mescaline ...........................................................................................................................................................................................
Methaqualone ....................................................................................................................................................................................
Methcathinone ...................................................................................................................................................................................
Methyldesorphine ...............................................................................................................................................................................
Methyldihydromorphine ......................................................................................................................................................................
Morphine methylbromide ...................................................................................................................................................................
Morphine methylsulfonate ..................................................................................................................................................................
Morphine-N-oxide ..............................................................................................................................................................................
N,N-Dimethylamphetamine ................................................................................................................................................................
Naphyrone .........................................................................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine ......................................................................................................................................................
N-Ethylamphetamine .........................................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ....................................................................................................................................
Noracymethadol .................................................................................................................................................................................
Norlevorphanol ...................................................................................................................................................................................
Normethadone ...................................................................................................................................................................................
Normorphine ......................................................................................................................................................................................
para-Fluorofentanyl ............................................................................................................................................................................
Parahexyl ...........................................................................................................................................................................................
PB-22; QUPIC ...................................................................................................................................................................................
Pentedrone ........................................................................................................................................................................................
Pentylone ...........................................................................................................................................................................................
Phenomorphan ..................................................................................................................................................................................
Pholcodine .........................................................................................................................................................................................
Psilocybin ...........................................................................................................................................................................................
Psilocyn ..............................................................................................................................................................................................
SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) .........................................................................................
SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) ............................................................................................................
Tetrahydrocannabinols ......................................................................................................................................................................
Thiofentanil ........................................................................................................................................................................................
THJ-2201 ( [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) ..................................................................................
Tilidine ................................................................................................................................................................................................
Trimeperidine .....................................................................................................................................................................................
U-47700 .............................................................................................................................................................................................
UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ....................................................................................
56,200,000
45
2
2
30
35
45
45
30
30
35
30
30
30
40
30
30
30
472,000
30
25
60
25
5
2
5
5
350
25
25
5
24
24
2
55
2
40
25
5
20
25
25
2
5
30
50
45
30
409,000
25
30
25
2
30
25
ethrower on DSK3G9T082PROD with NOTICES
Schedule II
1-Phenylcyclohexylamine ..................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ..................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .......................................................................................................................................
Alfentanil ............................................................................................................................................................................................
Alphaprodine ......................................................................................................................................................................................
Amobarbital ........................................................................................................................................................................................
Amphetamine (for conversion) ..........................................................................................................................................................
Amphetamine (for sale) .....................................................................................................................................................................
Carfentanil ..........................................................................................................................................................................................
Cocaine ..............................................................................................................................................................................................
Codeine (for conversion) ...................................................................................................................................................................
Codeine (for sale) ..............................................................................................................................................................................
Dextropropoxyphene ..........................................................................................................................................................................
VerDate Sep<11>2014
16:18 Nov 02, 2017
Jkt 244001
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
E:\FR\FM\03NON1.SGM
03NON1
4
4
1,050,000
4,200
2
20,100
12,000,000
42,400,000
20
103,400
40,000,000
45,000,000
35
Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices
51297
Final revised
2017 quotas
(g)
Basic class
Dihydrocodeine ..................................................................................................................................................................................
Dihydroetorphine ................................................................................................................................................................................
Diphenoxylate (for conversion) ..........................................................................................................................................................
Diphenoxylate (for sale) .....................................................................................................................................................................
Ecgonine ............................................................................................................................................................................................
Ethylmorphine ....................................................................................................................................................................................
Etorphine Hydrochloride ....................................................................................................................................................................
Fentanyl .............................................................................................................................................................................................
Glutethimide .......................................................................................................................................................................................
Hydrocodone (for conversion) ...........................................................................................................................................................
Hydrocodone (for sale) ......................................................................................................................................................................
Hydromorphone .................................................................................................................................................................................
Isomethadone ....................................................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ......................................................................................................................................................
Levomethorphan ................................................................................................................................................................................
Levorphanol .......................................................................................................................................................................................
Lisdexamfetamine ..............................................................................................................................................................................
Meperidine .........................................................................................................................................................................................
Meperidine Intermediate-A ................................................................................................................................................................
Meperidine Intermediate-B ................................................................................................................................................................
Meperidine Intermediate-C ................................................................................................................................................................
Metazocine .........................................................................................................................................................................................
Methadone (for sale) .........................................................................................................................................................................
Methadone Intermediate ....................................................................................................................................................................
Methamphetamine .............................................................................................................................................................................
360,000
2
15,000
1,110,000
99,000
30
32
1,350,000
2
122,000
51,900,000
5,140,800
30
5
30
12,900
19,000,000
2,904,000
5
30
5
15
23,700,000
28,700,000
1,539,100
[900,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 600,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 39,100 grams for methamphetamine (for sale)]
Methylphenidate .................................................................................................................................................................................
Morphine (for conversion) ..................................................................................................................................................................
Morphine (for sale) ............................................................................................................................................................................
Nabilone .............................................................................................................................................................................................
Noroxymorphone (for conversion) .....................................................................................................................................................
Noroxymorphone (for sale) ................................................................................................................................................................
Opium (powder) .................................................................................................................................................................................
Opium (tincture) .................................................................................................................................................................................
Oripavine ............................................................................................................................................................................................
Oxycodone (for conversion) ..............................................................................................................................................................
Oxycodone (for sale) .........................................................................................................................................................................
Oxymorphone (for conversion) ..........................................................................................................................................................
Oxymorphone (for sale) .....................................................................................................................................................................
Pentobarbital ......................................................................................................................................................................................
Phenazocine ......................................................................................................................................................................................
Phencyclidine .....................................................................................................................................................................................
Phenmetrazine ...................................................................................................................................................................................
Phenylacetone ...................................................................................................................................................................................
Racemethorphan ...............................................................................................................................................................................
Racemorphan ....................................................................................................................................................................................
Remifentanil .......................................................................................................................................................................................
Secobarbital .......................................................................................................................................................................................
Sufentanil ...........................................................................................................................................................................................
Tapentadol .........................................................................................................................................................................................
Thiafentanil ........................................................................................................................................................................................
Thebaine ............................................................................................................................................................................................
73,000,000
27,300,000
35,000,000
19,000
17,700,000
400,000
90,000
500,000
28,900,000
2,610,000
101,500,000
23,000,000
3,600,000
27,500,000
5
35
25
40
5
5
3,000
172,002
4,000
18,600,000
30
100,000,000
ethrower on DSK3G9T082PROD with NOTICES
List I Chemicals
Ephedrine (for conversion) ................................................................................................................................................................
Ephedrine (for sale) ...........................................................................................................................................................................
Phenylpropanolamine (for conversion) ..............................................................................................................................................
Phenylpropanolamine (for sale) .........................................................................................................................................................
Pseudoephedrine (for conversion) ....................................................................................................................................................
Pseudoephedrine (for sale) ...............................................................................................................................................................
VerDate Sep<11>2014
16:18 Nov 02, 2017
Jkt 244001
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
E:\FR\FM\03NON1.SGM
03NON1
50,000
4,810,000
13,600,000
7,000,000
40
186,000,000
51298
Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices
Aggregate production quotas for all
other schedule I and II controlled
substances included in 21 CFR 1308.11
and 1308.12 remain at zero.
Dated: October 27, 2017.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2017–24009 Filed 11–2–17; 8:45 am]
BILLING CODE 4410–09–P
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on March
17, 2017, Rhodes Technologies, 498
Washington Street, Coventry, Rhode
Island 02816 applied to be registered as
an importer the following basic classes
of controlled substances:
DEPARTMENT OF JUSTICE
Controlled
substance
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Rhodes Technologies
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before December 4, 2017. Such
persons may also file a written request
for a hearing on the application on or
before December 4, 2017.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
Comments and requests for hearings on
applications to import narcotic raw
material are not appropriate. 72 FR 3417
(January 25, 2007).
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
ethrower on DSK3G9T082PROD with NOTICES
DATES:
VerDate Sep<11>2014
16:18 Nov 02, 2017
Jkt 244001
Drug code
Tetrahydrocannabinols.
Methylphenidate
Oxycodone .......
Hydromorphone
Hydrocodone ....
Morphine ...........
Oxymorphone ...
Opium, raw .......
Poppy Straw
Concentrate.
Schedule
7370
I
1724
9143
9150
9193
9300
9652
9600
9670
II
II
II
II
II
II
II
II
The company plans to import opium,
raw (9600) and poppy straw concentrate
(9670) in order to bulk manufacture
controlled substances in Active
Pharmaceutical Ingredient (API) form.
The company distributes the
manufactured APIs in bulk to its
customers. The company plans to
import the other listed controlled
substances for internal reference
standards use only. The comparisons of
foreign reference standards to the
company’s domestically manufacture
API will allow the company to export
domestically manufacture API to foreign
markets.
control laws at United Rolls’ iron
foundry facility in Canton, Ohio. The
Complaint alleges violations of
recordkeeping and reporting
requirements, as well as failure to meet
requirements for the control of
particulate matter emissions from
United Rolls’ facility. The proposed
Consent Decree would require United
Rolls to perform emissions testing,
upgrade an air pollution control
monitoring system, and take other steps
to control air pollutant emissions from
its Canton facility. United Rolls also
would pay a total of $310,000 in civil
penalties (with $186,000 payable to the
United States and $124,000 payable to
the State).
The publication of this notice opens
a period for public comment on the
proposed Consent Decree. Comments
should be addressed to the Acting
Assistant Attorney General,
Environment and Natural Resources
Division, and should refer to United
States and the State of Ohio v. United
Rolls Inc., D.J. Ref. No. 90–5–2–1–
10704. All comments must be submitted
no later than thirty (30) days after the
publication date of this notice.
Comments may be submitted either by
email or by mail:
To submit
comments:
Send them to:
By email .......
pubcomment-ees.enrd@
usdoj.gov.
Assistant Attorney General,
U.S. DOJ—ENRD, P.O.
Box 7611, Washington, DC
20044–7611.
By mail .........
Dated: October 31, 2017.
Demetra Ashley,
Acting Assistant Administrator.
During the public comment period,
the proposed Consent Decree may be
BILLING CODE 4410–09–P
examined and downloaded at this
Justice Department Web site: https://
www.justice.gov/enrd/consent-decrees.
DEPARTMENT OF JUSTICE
We will provide a paper copy of the
Consent Decree upon written request
Notice of Lodging of Proposed
and payment of reproduction costs.
Consent Decree Under the Clean Air
Please mail your request and payment
Act
to: Consent Decree Library, U.S. DOJ—
On October 27, 2017, the Department
ENRD, P.O. Box 7611, Washington, DC
of Justice lodged a proposed Consent
20044–7611.
Decree with the United States District
Please enclose a check or money order
Court for the Northern District of Ohio
for $16.25 (25 cents per page
in the lawsuit entitled United States and
reproduction cost) payable to the United
the State of Ohio v. United Rolls Inc.,
States Treasury.
Civil Action No. 5:17–cv–02278.
The United States and the State of
Randall M. Stone,
Ohio filed a Complaint seeking civil
Acting Assistant Section Chief,
penalties and injunctive relief from
Environmental Enforcement Section,
Defendant United Rolls Inc. for alleged
Environment and Natural Resources Division.
violations of the Clean Air Act, 42
[FR Doc. 2017–23915 Filed 11–2–17; 8:45 am]
U.S.C. 7401–7671q, and corresponding
BILLING CODE 4410–15–P
provisions of Ohio’s air pollution
[FR Doc. 2017–24012 Filed 11–2–17; 8:45 am]
PO 00000
Frm 00089
Fmt 4703
Sfmt 9990
E:\FR\FM\03NON1.SGM
03NON1
]]>Agencies
[Federal Register Volume 82, Number 212 (Friday, November 3, 2017)]
[Notices]
[Pages 51293-51298]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-24009]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-470F]
Final Adjusted Aggregate Production Quotas for Schedule I and II
Controlled Substances and Assessment of Annual Needs for the List I
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2017
AGENCY: Drug Enforcement Administration (DEA), Department of Justice
(DOJ).
ACTION: Final order.
-----------------------------------------------------------------------
SUMMARY: This final order establishes the final adjusted 2017 aggregate
production quotas for controlled substances in schedules I and II of
the Controlled Substances Act and the assessment of annual needs for
the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine.
DATES: This order is applicable November 3, 2017.
FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Diversion Control
Division, Drug Enforcement Administration, 8701 Morrissette Drive,
Springfield, VA 22152, Telephone: (202) 598-6812.
SUPPLEMENTARY INFORMATION:
Legal Authority
Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826)
requires the Attorney General to establish aggregate production quotas
for each basic class of controlled substances listed in schedules I and
II and for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine. The Attorney General has delegated this function
to the Administrator of the Drug Enforcement Administration (DEA)
pursuant to 28 CFR 0.100.
Background
The DEA published the 2017 established aggregate production quotas
for controlled substances in schedules I and II and for the assessment
of annual needs for the list I chemicals ephedrine, pseudoephedrine,
and phenylpropanolamine in the Federal Register on October 5, 2016. 81
FR 69079. This notice stated that the
[[Page 51294]]
Administrator would adjust, as needed, the established aggregate
production quotas in 2017 in accordance with 21 CFR 1303.13 and 21 CFR
1315.13. The 2017 proposed adjusted aggregate production quotas for
controlled substances in schedules I and II and assessment of annual
needs for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine were subsequently published in the Federal Register
on August 4, 2017, (82 FR 36449) in consideration of the outlined
criteria. All interested persons were invited to comment on or object
to the proposed adjusted aggregate production quotas and assessment of
annual needs on or before September 5, 2017.
Comments Received
Three DEA-registered entities submitted timely comments regarding a
total of eleven schedule I and II controlled substances. Comments
received proposed that the aggregate production quotas for amphetamine
(for conversion), dihydrocodeine, diphenoxylate (for sale), heroin,
levorphanol, lisdexamfetmine, methadone intermediate, noroxymorphone
(for conversion), oripavine, oxycodone (for sale), and oxymorphone (for
conversion) were insufficient to provide for the estimated medical,
scientific, research, and industrial needs of the United States, for
export requirements, and for the establishment and maintenance of
reserve stocks. The DEA received 43 comments from non-DEA registered
entities in response to the DEA's August 4, 2017, press release for the
proposed 2018 aggregate production quotas. The majority of these
commenters expressed concerns about the 20 percent decrease to the
production quotas of controlled substances. The DEA also received two
comments from non-DEA registered entities suggesting that the
rescheduling of marihuana would drastically reduce opioid use, misuse,
and addiction. These 45 comments addressed issues that were outside the
scope of this final order, and therefore are not relevant to the
analysis involved in finalizing the 2017 aggregate production quotas.
The DEA received no comments from DEA-registered or non-DEA
registered entities for previously established values of the 2017
assessment of annual needs for ephedrine, pseudoephedrine, and
phenylpropanolamine.
Analysis for Final Adjusted 2017 Aggregate Production Quotas and
Assessment of Annual Needs
In determining the final adjusted 2017 aggregate production quotas
and assessment of annual needs, the DEA has taken into consideration
the above comments that are specifically relevant to this Final Order
for calendar year 2017 along with the factors set forth in 21 CFR
1303.13 and 21 CFR 1315.13 in accordance with 21 U.S.C. 826(a), and
other relevant factors including the 2016 year-end inventories, initial
2017 manufacturing and import quotas, 2017 export requirements, actual
and projected 2017 sales, research and product development
requirements, and additional applications received. Based on all of the
above, the Administrator is adjusting the 2017 aggregate production
quotas and assessment of annual needs for 4-Anilino-N-Phenethyl-4-
Piperidine (ANPP), dihydrocodeine, ephedrine (for sale), fentanyl,
hydrocodone (for sale), meperidine, methadone intermediate, morphine
(for sale), opium (tincture), Oripavine, oxycodone (for sale),
Oxymorphone (for conversion), Oxymorphone (for sale),
phenylpropanolamine (for conversion), phenylpropanolamine (for sale),
pseudoephedrine (for sale), tapentadol, and thiafentanil. This final
order reflects those adjustments.
Regarding diphenoxylate (for sale), heroin, levorphanol, and
noroxymorphone (for conversion) the Administrator hereby determines
that the proposed adjusted 2017 aggregate production quotas and
assessment of annual needs for these substances and list I chemicals as
published on August 4, 2017, (82 FR 36449) are sufficient to meet the
current 2017 estimated medical, scientific, research, and industrial
needs of the United States and to provide for adequate reserve stock.
This final order establishes these aggregate production quotas at the
same amounts as proposed.
Pursuant to the above, the Administrator hereby finalizes the 2017
aggregate production quotas for the following schedule I and II
controlled substances and the 2017 assessment of annual needs for the
list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine,
expressed in grams of anhydrous acid or base, as follows:
------------------------------------------------------------------------
Final revised
Basic class 2017 quotas (g)
------------------------------------------------------------------------
Schedule I
------------------------------------------------------------------------
1-(1-Phenylcyclohexyl)pyrrolidine...................... 10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)...... 30
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)..... 30
1-[1-(2-Thienyl)cyclohexyl]piperidine.................. 15
1-Benzylpiperazine..................................... 25
1-Methyl-4-phenyl-4-propionoxypiperidine............... 2
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)....... 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)...... 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)...... 30
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P).... 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)............... 30
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2- 25
methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B;
Cimbi-36).............................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)...... 30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2- 25
methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C;
Cimbi-82).............................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)........ 30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2- 30
methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;
Cimbi-5)..............................................
2,5-Dimethoxy-4-ethylamphetamine (DOET)................ 25
2,5-Dimethoxy-4-n-propylthiophenethylamine............. 25
2,5-Dimethoxyamphetamine............................... 25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T- 30
2)....................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C- 30
T-4)..................................................
3,4,5-Trimethoxyamphetamine............................ 25
3,4-Methylenedioxyamphetamine (MDA).................... 55
[[Page 51295]]
3,4-Methylenedioxymethamphetamine (MDMA)............... 50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)........... 40
3,4-Methylenedioxy-N-methylcathinone (methylone)....... 40
3,4-Methylenedioxypyrovalerone (MDPV).................. 35
3-FMC; 3-Fluoro-N-methylcathinone...................... 25
3-Methylfentanyl....................................... 30
3-Methylthiofentanyl................................... 30
4-Bromo-2,5-dimethoxyamphetamine (DOB)................. 25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)............. 25
4-Fluoroisobutyryl fentanyl............................ 30
4-FMC; Flephedrone..................................... 25
4-MEC; 4-Methyl-N-ethylcathinone....................... 25
4-Methoxyamphetamine................................... 150
4-Methyl-2,5-dimethoxyamphetamine (DOM)................ 25
4-Methylaminorex....................................... 25
4-Methyl-N-methylcathinone (mephedrone)................ 45
4-Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP).... 25
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 50
phenol................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 40
phenol (cannabicyclohexanol or CP-47,497 C8-homolog)..
5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H- 30
indazole-3-carboxamido)-3,3-dimethylbutanoate)........
5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 30
carboxamido)-3-methylbutanoate).......................
5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5- 30
fluoropentyl)-1H-indazole-3-carboxamide)..............
5-Fluoro-PB-22; 5F-PB-22............................... 20
5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3- 25
yl](2,2,3,3-tetramethylcyclopropyl)methanone..........
5-Methoxy-3,4-methylenedioxyamphetamine................ 25
5-Methoxy-N,N-diisopropyltryptamine.................... 25
5-Methoxy-N,N-dimethyltryptamine....................... 25
AB-CHMINACA............................................ 30
AB-FUBINACA............................................ 50
AB-PINACA.............................................. 30
Acetyl Fentanyl........................................ 100
Acetyl-alpha-methylfentanyl............................ 30
Acetyldihydrocodeine................................... 30
Acetylmethadol......................................... 2
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- 30
1-(4-fluorobenzyl)-1H-indazole-3-carboxamide).........
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- 50
pentyl-1H-indazole-3-carboxamide).....................
AH-7921................................................ 30
Allylprodine........................................... 2
Alphacetylmethadol..................................... 2
alpha-Ethyltryptamine.................................. 25
Alphameprodine......................................... 2
Alphamethadol.......................................... 2
alpha-Methylfentanyl................................... 30
alpha-Methylthiofentanyl............................... 30
alpha-Methyltryptamine (AMT)........................... 25
alpha-Pyrrolidinobutiophenone ([alpha]-PBP)............ 25
alpha-Pyrrolidinopentiophenone ([alpha]-PVP)........... 25
Aminorex............................................... 25
APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3- 25
carboxamide)..........................................
Benzylmorphine......................................... 30
Betacetylmethadol...................................... 2
beta-Hydroxy-3-methylfentanyl.......................... 30
beta-Hydroxyfentanyl................................... 30
beta-Hydroxythiofentanyl............................... 30
Betameprodine.......................................... 2
Betamethadol........................................... 4
Betaprodine............................................ 2
Bufotenine............................................. 3
Butylone............................................... 25
Butyryl Fentanyl....................................... 30
Cathinone.............................................. 24
Codeine Methylbromide.................................. 30
Codeine-N-oxide........................................ 330
Desomorphine........................................... 25
Diethyltryptamine...................................... 25
Difenoxin.............................................. 8,750
Dihydromorphine........................................ 1,566,000
Dimethyltryptamine..................................... 35
Dipipanone............................................. 5
Etorphine.............................................. 30
Fenethylline........................................... 30
Furanyl Fentanyl....................................... 30
[[Page 51296]]
gamma-Hydroxybutyric acid.............................. 56,200,000
Heroin................................................. 45
Hydromorphinol......................................... 2
Hydroxypethidine....................................... 2
Ibogaine............................................... 30
JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole)..... 35
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole)................ 45
JWH-073 (1-Butyl-3-(1-naphthoyl)indole)................ 45
JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole).... 30
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole)...... 30
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1- 35
naphthoyl)indole).....................................
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole)...... 30
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole)..... 30
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole)...... 30
Lysergic acid diethylamide (LSD)....................... 40
MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1- 30
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
carboxamide)..........................................
MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1- 30
(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-
dimethylbutanoate)....................................
MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole- 30
3-carboxamido)-3,3-dimethylbutanoate).................
Marihuana.............................................. 472,000
Mecloqualone........................................... 30
Mescaline.............................................. 25
Methaqualone........................................... 60
Methcathinone.......................................... 25
Methyldesorphine....................................... 5
Methyldihydromorphine.................................. 2
Morphine methylbromide................................. 5
Morphine methylsulfonate............................... 5
Morphine-N-oxide....................................... 350
N,N-Dimethylamphetamine................................ 25
Naphyrone.............................................. 25
N-Ethyl-1-phenylcyclohexylamine........................ 5
N-Ethylamphetamine..................................... 24
N-Hydroxy-3,4-methylenedioxyamphetamine................ 24
Noracymethadol......................................... 2
Norlevorphanol......................................... 55
Normethadone........................................... 2
Normorphine............................................ 40
para-Fluorofentanyl.................................... 25
Parahexyl.............................................. 5
PB-22; QUPIC........................................... 20
Pentedrone............................................. 25
Pentylone.............................................. 25
Phenomorphan........................................... 2
Pholcodine............................................. 5
Psilocybin............................................. 30
Psilocyn............................................... 50
SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2- 45
methoxyphenylacetyl)indole)...........................
SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)- 30
benzoyl]indole).......................................
Tetrahydrocannabinols.................................. 409,000
Thiofentanil........................................... 25
THJ-2201 ( [1-(5-fluoropentyl)-1H-indazol-3- 30
yl](naphthalen-1-yl)methanone)........................
Tilidine............................................... 25
Trimeperidine.......................................... 2
U-47700................................................ 30
UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3- 25
tetramethylcyclopropyl)methanone......................
------------------------------------------------------------------------
Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine................................ 4
1-Piperidinocyclohexanecarbonitrile.................... 4
4-Anilino-N-phenethyl-4-piperidine (ANPP).............. 1,050,000
Alfentanil............................................. 4,200
Alphaprodine........................................... 2
Amobarbital............................................ 20,100
Amphetamine (for conversion)........................... 12,000,000
Amphetamine (for sale)................................. 42,400,000
Carfentanil............................................ 20
Cocaine................................................ 103,400
Codeine (for conversion)............................... 40,000,000
Codeine (for sale)..................................... 45,000,000
Dextropropoxyphene..................................... 35
[[Page 51297]]
Dihydrocodeine......................................... 360,000
Dihydroetorphine....................................... 2
Diphenoxylate (for conversion)......................... 15,000
Diphenoxylate (for sale)............................... 1,110,000
Ecgonine............................................... 99,000
Ethylmorphine.......................................... 30
Etorphine Hydrochloride................................ 32
Fentanyl............................................... 1,350,000
Glutethimide........................................... 2
Hydrocodone (for conversion)........................... 122,000
Hydrocodone (for sale)................................. 51,900,000
Hydromorphone.......................................... 5,140,800
Isomethadone........................................... 30
Levo-alphacetylmethadol (LAAM)......................... 5
Levomethorphan......................................... 30
Levorphanol............................................ 12,900
Lisdexamfetamine....................................... 19,000,000
Meperidine............................................. 2,904,000
Meperidine Intermediate-A.............................. 5
Meperidine Intermediate-B.............................. 30
Meperidine Intermediate-C.............................. 5
Metazocine............................................. 15
Methadone (for sale)................................... 23,700,000
Methadone Intermediate................................. 28,700,000
Methamphetamine........................................ 1,539,100
------------------------------------------------------------------------
[900,000 grams of levo-desoxyephedrine for use in a non-controlled, non-
prescription product; 600,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 39,100 grams for
methamphetamine (for sale)]............................................
------------------------------------------------------------------------
Methylphenidate........................................ 73,000,000
Morphine (for conversion).............................. 27,300,000
Morphine (for sale).................................... 35,000,000
Nabilone............................................... 19,000
Noroxymorphone (for conversion)........................ 17,700,000
Noroxymorphone (for sale).............................. 400,000
Opium (powder)......................................... 90,000
Opium (tincture)....................................... 500,000
Oripavine.............................................. 28,900,000
Oxycodone (for conversion)............................. 2,610,000
Oxycodone (for sale)................................... 101,500,000
Oxymorphone (for conversion)........................... 23,000,000
Oxymorphone (for sale)................................. 3,600,000
Pentobarbital.......................................... 27,500,000
Phenazocine............................................ 5
Phencyclidine.......................................... 35
Phenmetrazine.......................................... 25
Phenylacetone.......................................... 40
Racemethorphan......................................... 5
Racemorphan............................................ 5
Remifentanil........................................... 3,000
Secobarbital........................................... 172,002
Sufentanil............................................. 4,000
Tapentadol............................................. 18,600,000
Thiafentanil........................................... 30
Thebaine............................................... 100,000,000
------------------------------------------------------------------------
List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion)............................. 50,000
Ephedrine (for sale)................................... 4,810,000
Phenylpropanolamine (for conversion)................... 13,600,000
Phenylpropanolamine (for sale)......................... 7,000,000
Pseudoephedrine (for conversion)....................... 40
Pseudoephedrine (for sale)............................. 186,000,000
------------------------------------------------------------------------
[[Page 51298]]
Aggregate production quotas for all other schedule I and II
controlled substances included in 21 CFR 1308.11 and 1308.12 remain at
zero.
Dated: October 27, 2017.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2017-24009 Filed 11-2-17; 8:45 am]
BILLING CODE 4410-09-P
